Clinical studies recruiting near Sutton

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Eli Lilly and Company · NCT07218380 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Bristol-Myers Squibb · NCT07106762 Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Wi
Phase 3 · Research Site · AstraZeneca · NCT07509151 Methods of T Cell Depletion Trial (MoTD)
Phase 2 · The Royal Marsden Hospital · University of Birmingham · NCT04888741 A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · Pharmacy: Royal Marsden Hospital · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Royal Marsden NHS Foundation Trust · Hoffmann-La Roche · NCT06793215 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · The Royal Marsden · CellCentric Ltd. · NCT04068597 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Eli Lilly and Company · NCT06890598 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · Local Institution - 4405 · Turning Point Therapeutics, Inc. · NCT03093116 A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide
Phase 1/Phase 2 · Celgene · NCT06988488 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorecta
Phase 1 · Royal Marsden Hospital · Hoffmann-La Roche · NCT04929223 A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced
Phase 1/Phase 2 · The Royal Marsden Hospital · BioNTech SE · NCT07186842 Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Phase 1/Phase 2 · The Royal Marsden NHS Foundation Trust · Institute of Cancer Research, United Kingdom · NCT06126731 A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Live
Phase 1 · Sutton · Bayer · NCT06764316 A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic P
Phase 1 · Royal Marsden Hospital - Surrey · Genentech, Inc. · NCT05800665 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C
Phase 3 · Merck Sharp & Dohme LLC · NCT06623422 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Royal Marsden Hospital · Janssen Research & Development, LLC · NCT06319820 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Royal Marsden Hospital · Daiichi Sankyo · NCT06731478 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · Royal Marsden Hospital · BioNTech SE · NCT07070232 DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adul
Phase 2/Phase 3 · The Royal Marsden Hospital · Cancer Research UK · NCT05786716 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Phase 3 · Royal Marsden Hospital · Gustave Roussy, Cancer Campus, Grand Paris · NCT04221035 A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combinatio
Phase 1 · Royal Marsden Hospital (Sutton) · Vividion Therapeutics, Inc. · NCT06004245 Beyond TME Origins
NA · Royal Marsden Hospital NHS Foundation Trust · Imperial College London · NCT02292641 CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
Phase N/A · The Royal Marsden NHS Foundation Trust, Downs Road · Royal Marsden NHS Foundation Trust · NCT05828628 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · The Royal Marsden Hospital - Drug Development Unit · Institute of Cancer Research, United Kingdom · NCT06630260 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · The Royal Marsden Hospital, Sutton · Boehringer Ingelheim · NCT07472517 First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant
Phase 1 · The Royal Marsden NHS Foundation Trust | Sutton - Oak Founda · Bayer · NCT06217822 Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Phase 4 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05803941 A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different
Phase 1 · The Royal Marsden Hospital, Sutton · Boehringer Ingelheim · NCT05471856 DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · The Royal Marsden Hospital · Cancer Research UK · NCT05770102

Look up another city

Look up another condition